SHAMILA SHANMUGAM: Open Payments
NPI 1417576380 · EL SEGUNDO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,480 in 158 payments from 17 companies in 2025. Trend: 2023 $988 · 2024 $1,146 · 2025 $3,480
Food & beverage: $3,380Education: $100
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $808 |
| GENZYME CORPORATION | 12 | $460 |
| Arcutis Biotherapeutics, Inc. | 17 | $416 |
| UCB, Inc. | 33 | $330 |
| Janssen Biotech, Inc. | 11 | $297 |
| Organon LLC | 5 | $212 |
| Incyte Corporation | 9 | $170 |
| Lilly USA, LLC | 7 | $155 |
| Galderma Laboratories, L.P. | 11 | $142 |
| LEO Pharma Inc. | 4 | $96 |
Products named: DUPIXENT, SKYRIZI, Zoryve, Bimzelx, TREMFYA, RINVOQ, VTAMA, OPZELURA.
Industry payments across CA — which companies pay providers there.
